- In recent months, Medtronic reported very large global revenue growth and significant U.S. market share gains in its Cardiac Ablation Solutions business, while progressing the planned separation of its MiniMed diabetes unit and renal denervation program.
- At the same time, Medtronic moved to within one dividend increase of Dividend King status after lifting its quarterly payout to US$0.72 per share in June 2026, underlining management’s emphasis on consistent shareholder returns.
- With Cardiac Ablation Solutions showing especially strong momentum, we’ll now examine how this development reshapes Medtronic’s broader investment narrative.
Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
Medtronic Investment Narrative Recap
To own Medtronic, you need to believe its diversified device portfolio and innovation in fast-growing areas like Cardiac Ablation Solutions can offset weaker segments and margin pressure. The latest 78% CAS revenue jump and U.S. share gains support that thesis and strengthen a key near term catalyst, but they do not eliminate execution risks in manufacturing, product ramps, or the pending Diabetes separation.
The recent dividend increase to US$0.72 per share, bringing Medtronic within one hike of Dividend King status, is especially relevant here. It signals continued commitment to shareholder payouts even as the company invests heavily in CAS, Hugo robotics, and renal denervation, putting a spotlight on whether cash generation can comfortably fund both growth initiatives and rising dividends over time.
Yet beneath the strong CAS headlines, investors should be aware that...
Read the full narrative on Medtronic (it's free!)
Medtronic's narrative projects $41.5 billion revenue and $6.6 billion earnings by 2029. This requires 4.5% yearly revenue growth and an earnings increase of about $1.8 billion from $4.8 billion today.
Uncover how Medtronic's forecasts yield a $98.00 fair value, a 4% upside to its current price.
Exploring Other Perspectives
The most cautious analysts were assuming only about 2% annual revenue growth to roughly US$38.6 billion by 2029 and earnings of US$6.2 billion, so if newer platforms like CAS and Affera strengthen further, their more pessimistic view of Medtronic’s potential may need to be revisited.
Explore 6 other fair value estimates on Medtronic - why the stock might be worth as much as $98.44!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Medtronic research is our analysis highlighting 5 key rewards that could impact your investment decision.
- Our free Medtronic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medtronic's overall financial health at a glance.
Want Some Alternatives?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
- Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Outshine the giants: these 17 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com